Comparing Dosing and Management of BCMA vs Non-BCMA Bispecific Antibodies

Opinion
Video

Panelists discuss how the evaluation and treatment initiation processes for non-BCMA targeted bispecifics and BCMA-targeted bispecifics share core similarities in patient assessment and care coordination, but differ in specific premedication protocols, dosing strategies, and side effect management.

Video content above is prompted by the following:

  • Is the process different/similar for patients who might be receiving non-BCMA targeted bispecific vs BCMA-bispecific?
  • Review any differences/similarities between bispecifics (non-BCMA vs BCMA) for step up dosing, premedication/prophylaxis, etc.
Recent Videos
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series
BCMA testing tracks clinical changes faster without the need for marker expression vs monoclonal immunoglobulin, a conventional multiple myeloma marker.
Studies indicate that higher BCMA levels are associated with a greater need for therapy years following diagnosis for patients with smoldering myeloma.
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
Related Content